HLS Therapeutics Inc (TSE:HLS) has released an update.
HLS Therapeutics Inc. has announced a significant expansion in the availability of its cardiovascular drug Vascepa, with Alberta’s public drug plan now covering the medication. This expansion means that over 90% of Canadians with public or private insurance will have access to the drug for the secondary prevention of cardiovascular events. The company emphasizes the importance of addressing cardiovascular disease, a leading cause of death in Canada, by improving national coverage for Vascepa.
For further insights into TSE:HLS stock, check out TipRanks’ Stock Analysis page.
